Original Article

You have full text access to this OnlineOpen article

High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk ewing sarcoma family tumors

The Bambino Gesù Children's Hospital experience

  1. Giuseppe Maria Milano M.D.1,†,*,
  2. Raffaele Cozza M.D.1,
  3. Ilaria Ilari M.D.1,
  4. Luigi De Sio M.D.1,
  5. Renata Boldrini M.D.2,
  6. Alessandro Jenkner M.D.1,
  7. Maretta De Ioris M.D.1,
  8. Alessandro Inserra M.D.3,
  9. Carlo Dominici M.D.1,4,
  10. Alberto Donfrancesco M.D.1

Article first published online: 10 MAR 2006

DOI: 10.1002/cncr.21780

Issue

Cancer

Cancer

Volume 106, Issue 8, pages 1838–1845, 15 April 2006

Additional Information

How to Cite

Milano, G. M., Cozza, R., Ilari, I., De Sio, L., Boldrini, R., Jenkner, A., De Ioris, M., Inserra, A., Dominici, C. and Donfrancesco, A. (2006), High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk ewing sarcoma family tumors. Cancer, 106: 1838–1845. doi: 10.1002/cncr.21780

Author Information

  1. 1

    Division of Pediatric Oncology, Ospedale Pediatrico Bambino Gesù-IRCCS, Rome, Italy

  2. 2

    Division of Pathology, Ospedale Pediatrico Bambino Gesù-IRCCS, Rome, Italy

  3. 3

    Division of Pediatric Surgery, Ospedale Pediatrico Bambino Gesù-IRCCS, Rome, Italy

  4. 4

    Department of Pediatrics, La Sapienza University, Rome, Italy

  1. †

    Fax: (011) 396 68592242

*Dipartimento di Oncoematologia Pediatrica e Servizio Immunotrasfusionale, UO di Oncologia, Ospedale Pediatrico Bambino Gesù-IRCCS, Piazza Sant'Onofrio 4, Rome, 00165, Italy

Publication History

  1. Issue published online: 4 APR 2006
  2. Article first published online: 10 MAR 2006
  3. Manuscript Accepted: 2 NOV 2005
  4. Manuscript Revised: 28 OCT 2005
  5. Manuscript Received: 19 JUL 2005

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (127K)

REFERENCES

  • 1
    Pizzo A, Poplack DG. Principles and practice of pediatric oncology. 4th ed. Philadelphia: Lippincott-Raven; 2003.
  • 2
    Dehner LP. Primitive neuroectodermal tumors and Ewing's sarcoma. Am J Surg Pathol. 1993; 17: 1-13.
  • 3
    Delattre O, Zucman J, Melot T, et al. The Ewing family of tumors: a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med. 1994; 331: 294-299.
  • 4
    Picci P, Bohling T. Bacci, G, et al. Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. J Clin Oncol. 1997; 15: 1553-1559.
  • 5
    Picci P, Rougraff BT, Bacci G, et al. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J Clin Oncol. 1993; 11: 1763-1769.
  • 6
    Rosito P, Mancini AF, Rondelli R, et al. Italian Cooperative Study for the treatment of children and young adults with localized Ewing's sarcoma of bone: a preliminary report of 6 years of experience. Cancer. 1999; 86: 421-428.
    Direct Link:
  • 7
    Gobel V, Jurgens H, Etspuler G, et al. Prognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescents. J Cancer Res Clin Oncol. 1987; 113: 187-191.
  • 8
    Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol. 2000; 18, 3108-3114.
  • 9
    Paulussen M, Aherns S, Burdach S, et al. Primary metastatic (Stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. Ann Oncol. 1998; 9: 275-281.
  • 10
    Raney RB, Asmar L, Newton WA Jr., et al. Ewing's sarcoma of soft tissues in childhood: A report from the Intergroup Rhabdomyosarcoma Study, 1972 to 1991. J Clin Oncol. 1997; 15: 574-582.
  • 11
    Miser JS, Kinsella TJ, Triche TJ, et al. Treatment of primitive neuroepithelioma in children and young adults. J Clin Oncol. 1987; 5: 1752-1758.
  • 12
    Burgert EO, Nesbit ME, Garnsey LA, et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup Study IESS-II. J Clin Oncol. 1990; 8: 1514-1524.
  • 13
    Craft AW, Cotterill S, Imeson J. Improvement in survival for Ewing's sarcoma by substitution of ifosfamide for cyclophosphamide. Am J Pediatr Hematol Oncol. 1993; 15: 31-35.
  • 14
    Elomaa I, Blomqvist CP. Saeter, G, et al. Five-year results in Ewing's sarcoma. The Scandinavian Sarcoma Group Experience with the SSG-IX protocol. Eur J Cancer. 2000; 36: 875-880.
  • 15
    Sandoval C, Meyer WH, Parham DM, et al. Outcome in 43 children presenting with metastatic Ewing sarcoma: the St. Jude Children's Research Hospital experience, 1962 to 1992. Med Pediatr Oncol. 1996; 26: 180-185.
    Direct Link:
  • 16
    Jenkin RD, Al-Fawaz I, Al-Shabanah MO, et al. Metastatic Ewing sarcoma/PNET of bone at diagnosis: prognostic factors—a report from Saudi Arabia. Med Pediatr Oncol. 2001; 37: 383-389.
    Direct Link:
  • 17
    Paulussen M, Aherns S, Craft AW, et al. Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J Clin Oncol. 1998; 16: 3044-3052.
  • 18
    Pinkerton CR, Bataillard A, Guillo S, et al. Treatment strategies for metastatic Ewing's sarcoma. Eur J Cancer. 2001; 37: 1338-1344.
  • 19
    Burdach S, van Kaick B, Laws HJ, et al. Allogeneic and autologous stem cell transplantation in advanced Ewing tumor: an update after long-term follow-up from two centers of the European Intergroup Study EICESS. Ann Oncol. 2000; 11: 1451-1462.
  • 20
    Hawkins D, Barnett T, Bensinger W, et al. Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-sarcoma-family tumors. Med Pediatr Oncol. 2000; 34: 328-337.
    Direct Link:
  • 21
    Kolb EA, Kushner BH, Gorlick G. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol. 2003; 21: 3423-3430.
  • 22
    Kushner BH, Meyers PA, Gerald WL, et al. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. J Clin Oncol. 1995; 13: 2796-2804.
  • 23
    Kung FH, Desai SJ, Dickerman JD, et al. Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study. J Pediatr Hematol Oncol. 1995; 17: 265-269.
  • 24
    Abu-Ghosh AM, Krailo MD, Goldman SC, et al. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report. Ann Oncol. 2002; 13: 460-469.
  • 25
    Van Winkle P, Angiolillo A, Krailo M, et al. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. Pediatr Blood Cancer. 2005; 44: 338-347.
    Direct Link:
  • 26
    Cairo MS, Shen V, Krailo MD, et al. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a Children's Cancer Group report. J Pediatr Hematol Oncol. 2001; 23: 30-38.
  • 27
    Collett D. Modelling survival data in medical research. London: Chapman & Hall/CRC; 1994.
  • 28
    Kaplan EL, Meier P. Non-parametric estimations from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 29
    Sailer SL, Harmon DC, Mankin HJ, et al. Ewing's sarcoma: surgical resection as a prognostic factor. Int J Radiat Oncol Biol Phys. 1988; 15: 43-52.
  • 30
    Dunst J, Hoffmann C, Ahrens S, Jurgens H. Surgery versus radiotherapy in Ewing's sarcoma with good prognosis. Analysis of the CESS 86 data. Strahlenther Onkol. 1996; 172: 244-248.
  • 31
    Dunst J, Sauer R, Burgers JMV, et al. Radiation therapy as local treatment of Ewing's sarcoma: results of the Cooperative Ewing's Sarcoma Study CESS 81 and CESS 86. Cancer. 1991; 67: 2818-2825.
    Direct Link:
  • 32
    Scully SP, Temple HT, O'Keefe RJ, et al. Role of surgical resection in pelvic Ewing's sarcoma. J Clin Oncol. 1995; 13: 2336-2341.
  • 33
    Ozaki T, Hillmann A, Hoffmann C, et al. Significance of surgical margin on the prognosis of patients with Ewing's sarcoma: a report from the Cooperative Ewing's Sarcoma Study. Cancer. 1996; 78: 892-900.
    Direct Link:
  • 34
    Givens SS, Woo SY, Huang LY, et al. Non-metastatic Ewing's sarcoma: twenty years of experience suggests that surgery is a prime factor for successful multimodality therapy. Int J Oncol. 1999; 14: 1039-1043.
  • 35
    Fields KK, Zorsky PE, Hiemenz JW, et al. Ifosfamide, carboplatin, and etoposide: a new regimen with a broad spectrum of activity. J Clin Oncol. 1994; 12: 544-552.
  • 36
    Kung FH, Pratt CB, Vega RA, et al. Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study. Cancer. 1993; 71: 1898-1903.
    Direct Link:
  • 37
    Marina NM, Rodman J, Shema SJ, et al. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. J Clin Oncol. 1993; 11: 554-560.
View Full Article (HTML) Get PDF (127K)